Latest Healthcare News

Elanor Investors Group reported a $57 million statutory loss for FY25 but is progressing a $125 million recapitalisation with Rockworth Capital Partners to stabilise its balance sheet amid ongoing financial challenges.

Winton Land Limited has secured conditional approval under the Fast-track Approvals Act 2024 for its Sunfield masterplanned community, paving the way for thousands of homes and extensive commercial precincts.

Tetratherix Limited has raised approximately $5 million to fast-track its Tutelix prostate spacer into pivotal clinical trials across Australia and the US, aiming to improve radiation therapy for prostate cancer patients.

Orthocell has appointed LEDA Orthopaedics as the exclusive distributor for its Remplir™ nerve repair product in the UK, positioning itself for a rapid commercial launch pending regulatory approval.

Clarity Pharmaceuticals has completed enrolment in its Phase III AMPLIFY trial for the Cu-SAR-bisPSMA imaging agent, advancing its bid for FDA approval in prostate cancer diagnostics.

Micro-X has reached a key development milestone with the completion of its first Full Body CT laboratory test bench, securing a $1.6 million payment from US government partner ARPA-H and advancing its innovative medical imaging program.

Cyclopharm Limited has responded to ASX queries clarifying the material significance of its Technegas® contract with the US National Institutes of Health, while confirming robust progress in expanding its US footprint.

Audeara Limited has initiated three new white-label Auracast™ programs with Clinico Inc., alongside launching its BT-03 Audio Broadcaster in Australia, marking a significant step in scaling its audio technology globally.

Rhythm Biosciences has achieved a significant regulatory milestone with NATA accreditation for its ColoSTAT® blood-based colorectal cancer test, enabling its commercial rollout in Australia and strengthening reimbursement prospects.

A new clinical study from Sichuan University confirms that TruScreen’s AI-enabled cervical cancer screening combined with high-risk HPV testing outperforms traditional cytology methods, reinforcing its global potential.

Pro Medicus Limited’s U.S. subsidiary has locked in two significant 5-year contract renewals worth a combined minimum of A$40 million, reinforcing its position in the competitive medical imaging market.

S&P Dow Jones Indices has announced its March 2026 quarterly rebalance, reshuffling key constituents across major S&P/ASX indices effective March 23. The update signals shifts in market representation with notable additions and removals.